High Incidence of Scrapie Induced by Repeated Injections of Subinfectious Prion Doses†

Catherine Jacquemot,1,2 Céline Cuche,2 Dominique Dormont,3 and Françoise Lazarini1,2*


Received 3 November 2004/Accepted 16 March 2005

To clarify the mechanisms leading to the development of Creutzfeldt-Jakob disease in some recipients of pituitary-derived human growth hormone (hGH), we investigated the effects of repeated injections of low prion doses in mice. The injections were performed, as in hGH-treated children, by a peripheral route at short intervals and for an extended period. Twelve groups of 24 mice were intraperitoneally inoculated one, two, or five times per week for 200 days with 2 × 10⁻⁵ to 2 × 10⁻⁸ dilutions of brain homogenate containing the mouse-adapted C506M3 scrapie strain. Sixteen control mice were inoculated once a week for 200 days with a 2 × 10⁻⁴ dilution of normal brain homogenate. Of mice injected in a single challenge with a scrapie inoculum of a 2 × 10⁻⁴, 2 × 10⁻⁵, or 2 × 10⁻⁶ dilution, 2/10, 1/10, and 0/10 animals developed scrapie, respectively. Control mice remained healthy. One hundred thirty-five of 135 mice injected with repeated prion doses of a 2 × 10⁻⁵ or 2 × 10⁻⁶ dilution succumbed to scrapie. Of mice injected with repeated scrapie doses of a 2 × 10⁻⁷ or 2 × 10⁻⁸ dilution, 52/59 and 38/67 animals died of scrapie, respectively. A high incidence of scrapie was observed in mice receiving repeated doses at low infectivity, whereas there was no disease in mice that were injected once with the same doses. Repeated injections of low prion doses thus constitute a risk for development of prion disease even if the same total dose inoculated in a single challenge does not induce the disease.

Creutzfeldt-Jakob disease (CJD) is a rare transmissible dementia due to unconventional pathogenic agents called prions. It belongs to the group of transmissible spongiform encephalopathies, which also comprises scrapie in sheep and bovine spongiform encephalopathy in cattle. CJD occurs as a sporadic, familial, or iatrogenic form (iCJD). Since 1985, more than 160 cases of CJD transmitted iatrogenically by pituitary human growth hormone (hGH) have been described in a number of countries, including France, the United States, and the United Kingdom, with the majority of cases occurring in France (5, 24). Since 1985, more than 160 cases of CJD transmitted iatrogenically by pituitary human growth hormone (hGH) have been described in a number of countries, including France, the United States, and the United Kingdom, with the majority of cases occurring in France (5, 24). Since 1985, more than 160 cases of CJD transmitted iatrogenically by pituitary human growth hormone (hGH) have been described in a number of countries, including France, the United States, and the United Kingdom, with the majority of cases occurring in France (5, 24). Since 1985, more than 160 cases of CJD transmitted iatrogenically by pituitary human growth hormone (hGH) have been described in a number of countries, including France, the United States, and the United Kingdom, with the majority of cases occurring in France (5, 24).

To clarify the mechanisms leading to the development of Creutzfeldt-Jakob disease in some recipients of pituitary-derived human growth hormone (hGH), we investigated the effects of repeated injections of low prion doses in mice. The injections were performed, as in hGH-treated children, by a peripheral route at short intervals and for an extended period. Twelve groups of 24 mice were intraperitoneally inoculated one, two, or five times per week for 200 days with 2 × 10⁻⁵ to 2 × 10⁻⁸ dilutions of brain homogenate containing the mouse-adapted C506M3 scrapie strain. Sixteen control mice were inoculated once a week for 200 days with a 2 × 10⁻⁴ dilution of normal brain homogenate. Of mice injected in a single challenge with a scrapie inoculum of a 2 × 10⁻⁴, 2 × 10⁻⁵, or 2 × 10⁻⁶ dilution, 2/10, 1/10, and 0/10 animals developed scrapie, respectively. Control mice remained healthy. One hundred thirty-five of 135 mice injected with repeated prion doses of a 2 × 10⁻⁵ or 2 × 10⁻⁶ dilution succumbed to scrapie. Of mice injected with repeated scrapie doses of a 2 × 10⁻⁷ or 2 × 10⁻⁸ dilution, 52/59 and 38/67 animals died of scrapie, respectively. A high incidence of scrapie was observed in mice receiving repeated doses at low infectivity, whereas there was no disease in mice that were injected once with the same doses. Repeated injections of low prion doses thus constitute a risk for development of prion disease even if the same total dose inoculated in a single challenge does not induce the disease.

Materials and Methods

Animals. C57BL/6 mice at 6 weeks of age (Janvier, France) were used for this study. All animals were housed in level 3 care facilities of the Pasteur Institute, officially registered for prion experimental studies of rodents (Ministry agreement number A 75-15-27 for animal care facilities; agreement number 75-585 for animal experimentation).

Infectious material. The mouse-adapted scrapie strain C506M3 was stabilized and propagated in the C57BL/6 mouse line (17). The inoculum was a brain homogenate at 10% (wt/vol) in 5% glucose solution from a mouse with scrapie...
at the terminal stage of disease, routinely titrating $10^8$ to $5 \times 10^9$ 50% lethal doses ($LD_{50}$) per gram in intracerebral-infection challenges (8, 15). The mean survival time was around $173 \pm 5$ (standard deviation [SD]) days after intracerebral infection or $333 \pm 7$ (SD) days after intraperitoneal challenge (8, 17). Healthy mouse brain homogenate was used for the negative controls.

**Procedures.** Twelve groups of 24 mice were inoculated by the intraperitoneal route one, two, or five times per week for 200 days with the mouse-adapted C506M3 scrapie strain. The inoculations were performed every Monday for the 1-injection-per-week schedule, every Monday and Wednesday for the 2-injections-per-week schedule, and every day from Monday to Friday for the 5-injections-per-week schedule. The injected prion doses (50 μl) ranged from $10^{-3}$ to $10^{-2}$ mg of brain to $10^{-4}$ to $10^{-5}$ dilutions of the scrapie brain homogenate used as the inoculum. Three groups of 10 to 11 mice were injected once with scrapie inoculum dilutions of $2 \times 10^{-4}$, $2 \times 10^{-5}$, and $2 \times 10^{-6}$, respectively. Sixteen control mice received by the same route a $2 \times 10^{-4}$ dilution of normal brain homogenate once a week for 200 days.

**Scrapie diagnosis.** Animals were examined three times per week for clinical signs of scrapie, which could include bradykinesia, waddling gait, poor coat condition, terminal incoordination, and weight loss. Scrapie-infected mice, animals died of scrapie, respectively. The high number of injections per week (200 days, 24/24, 24/24, and 18/18 animals died of scrapie, indicating the absence of any background laboratory contamination. Of mice injected in a single challenge with a scrapie inoculum of a $2 \times 10^{-4}$, $2 \times 10^{-5}$, or $2 \times 10^{-6}$ dilution, only 2/10, 1/10, and 0/10 animals developed scrapie. Animals that did not show any clinical signs of scrapie were all negative for the presence of PrPsc. Compared to the $5 \times 10^9$ mean $LD_{50}$ per gram in intracerebral-infection challenges, these results indicate that intraperitoneal injection of the C506M3 scrapie strain is $10^3$ times less efficient than intracerebral inoculation (8, 15).

These data are very similar to previous findings with other mouse-adapted scrapie strains (14). While a single injection of a $2 \times 10^{-5}$ dilution scrapie dose induced scrapie in 10% of the injected animals, repeated injections of the same dose led to a 100% transmission rate for scrapie (Table 1). Of mice injected with a scrapie inoculum of a $2 \times 10^{-5}$ dilution one, two, and five times per week for 200 days, 24/24, 24/24, and 18/18 animals died of scrapie, respectively. The high number of injec-

**RESULTS**

The effect of intraperitoneal injections of repeated subinfectious doses of the C506M3 scrapie strain was investigated in mice. Our results are summarized in Table 1. Figure 1 shows a representative scrapie diagnosis by proteinase K digestion of brain samples. None of the 16 mice injected with normal brain homogenate developed scrapie, indicating the absence of any background laboratory contamination. Of mice injected in a single challenge with a scrapie inoculum of a $2 \times 10^{-4}$, $2 \times 10^{-5}$, or $2 \times 10^{-6}$ dilution, only 2/10, 1/10, and 0/10 animals developed scrapie. Animals that did not show any clinical signs of scrapie were all negative for the presence of PrPsc.

![FIG. 1. Western blot diagnosis after proteinase K (PK) digestion; 0.1 mg of brain was plotted in each lane. Detection of PrP was done with SAB 32 and SAB 84 antibodies as described in Materials and Methods. +, present; −, absent.](http://jvi.asm.org)
tions induced a significant decrease in the survival period, as the survival times for 28, 57, and 143 injections were 364 ± 19, 339 ± 20, and 310 ± 21 (SD) days, respectively (P = 0.0001 for 57 injections versus 28 injections; P < 0.0001 for 143 versus 28 injections; permutation test).

For increased dilutions of the infectious material, repeated injections resulted in a high incidence of scrapie, while the same doses inoculated in a single challenge did not induce the disease. Thus, all mice survived after injection of 2.5 × 10⁻⁴ mg extract in a single dose while 21/23 animals developed the disease for 3.6 × 10⁻⁴ mg extract injected at 2.5 × 10⁻⁶ mg five times a week (Table 1). Increasing the dilution of the scrapie inoculum was associated with both a progressive decrease of the infection rate and a significant increase of the survival period. Of mice injected with a scrapie inoculum at 2 × 10⁻⁶ dilution one, two, and five times per week for 200 days, 24/24, 22/22, and 23/23 animals died of scrapie, respectively. Of mice injected with repeated scrapie doses of a 2 × 10⁻⁷ or 2 × 10⁻⁸ dilution, 52/59 and 38/67 animals succumbed to scrapie, respectively. Mice without clinical signs of scrapie were all negative for the presence of PrPSc. As shown in Fig. 2, the survival time was significantly shorter when the prion dose was high.

For instance, the survival time for one injection per week was 364 ± 19 days for the 2 × 10⁻⁵ dose dilution and 467 ± 57 (SD) days for the 2 × 10⁻⁸ dose dilution, respectively (P = 0.003; permutation test). Moreover, the scrapie incidence was significantly higher when the intervals between injections were shorter. As shown in Fig. 2, the survival time was also shorter when the number of inoculations was high. For instance, the survival time for a 2 × 10⁻⁷ dilution of infective material was 456 ± 72 days for 28 injections (1 injection per week) and 364 ± 32 (SD) days for 143 injections (5 injections per week), respectively (P = 0.0357; permutation test).

For all doses given, we found that the incidence of scrapie was higher when the total dose was injected as multiple challenges than when it was injected as a single challenge. For instance, scrapie was detected in 1/10 mice for a single injection at the cumulative dose of 2.5 × 10⁻³ mg of inoculum brain, in 9/21 mice for 28 injections (1 injection per week for 7 months) at a cumulative dose of 7 × 10⁻⁵ mg, in 8/23 mice for 57 injections (2 injections per week for 7 months) at a cumulative dose of 1.4 × 10⁻⁴ mg, and in 21/23 mice for 143 injections (5 injections per week for 7 months) at a cumulative dose of 3.6 × 10⁻⁴ mg (P < 0.0001 for 143 injections versus a

FIG. 2. Survival curves of mice intraperitoneally infected with different dilutions of scrapie inoculum. Twelve groups of 24 mice were inoculated one, two, or five times per week for 200 days with 2 × 10⁻⁷ to 2 × 10⁻¹ dilutions of brain homogenate containing the mouse-adapted C506M3 scrapie strain. Sixteen control mice were injected once a week for 200 days with a 2 × 10⁻⁴ dilution of normal brain homogenate and remained healthy. Three groups of 10 mice received a single injection of a 2 × 10⁻⁴, 2 × 10⁻⁵, or 2 × 10⁻⁶ dilution of scrapie inoculum.
single injection; \( P = 0.0006 \) for 143 injections versus 28 injections; \( P = 0.0001 \) for 143 injections versus 57 injections; Fisher’s exact test).

**DISCUSSION**

The high incidence of CJD in recipients of pituitary-derived hGH suggests a role of repeated injections of low prion doses in the development of this lethal disease. As no data were available on repeated low-prion-dose inoculations by injection, our aim was to evaluate the cumulative risk in an animal model and possibly to identify the number of PrPSc molecules involved in the spread of infectivity. Here, we show that a high incidence of scrapie cases occurred in mice receiving repeated low doses of prion material, whereas there was no disease in mice that were injected once with the same total dose. The risk of infection was clearly related to the level of exposure to prions, defined as the dose, the number of injections, and the interval between inoculations. Our findings are consistent with those of Diringer et al., who also reported a higher scrapie incidence in repeated oral infection of hamsters with scrapie compared to using a single dose (10). However, our results show a greater effect on scrapie incidence, which might be due to the route of administration. Comparison of data shows that repeated intraperitoneal infection is \( 10^3 \) to \( 10^4 \)-fold more effective than repeated oral infection. Interestingly, in agreement with the report that a single intraperitoneal dose is more efficient than an oral dose, our data indicate that the intraperitoneal route is probably more efficient than the oral route when using multiple doses (14). The risk of infection thus seems to be higher by injection of low prion doses than by ingestion of the same doses. The higher scrapie incidence in multiple intraperitoneal infection could also be related to the longer duration of prion administration in our experiment. We repeatedly treated mice with low-dose inocula for 7 months, whereas in Diringer’s study (10), repeated oral infection lasted only 10 days.

A single injection of very low doses of prions, such as \( 2.5 \times 10^{-4} \) mg of scrapie brain, did not lead to scrapie infection, which might reflect active or passive elimination of prions by the organism. Inoculated animals without clinical signs of scrapie were all negative for the presence of PrPSc, which suggests that a low-dose inoculum failed to induce a chronic subclinical prion disease in our mouse scrapie model. Subclinical scrapie infection was described in some low-dose infections with scrapie (13). It was characterized by high levels of infectivity and PrPSc without development of clinical signs of prion disease during a normal life span. Taylor et al. have reported intermittent mild or early clinical signs in mice inoculated with low doses of ME7 prion inoculum (22). Similarly, Thackray et al. have shown high levels of infectivity and PrPSc in PrP transgenic mice with subclinical disease following low-dose inoculation of ME7 or RML scrapie strains (23). The difference between these observations and our results is probably due to the scrapie and mouse strains and to the route of inoculation. In a single intracerebral injection, one LD\(_{50}\) unit contains about \( 10^9 \) PrPSc molecules in a hamster scrapie model (3). Our data suggest that intraperitoneal injection of a scrapie strain is \( 10^2 \) to \( 10^3 \) times less efficient than intracerebral inoculation. In a single intraperitoneal injection, one LD\(_{50}\) unit is thus likely to contain about \( 10^8 \) to \( 10^9 \) PrPSc molecules. At low-level infectivity, PrPSc clearance may prevent infection. Here, we found that multiple injections of doses of \(<10^{-4}\) LD\(_{50}\) may induce infection, and so repeated injections of only about \( 10^2 \) to \( 10^3 \) molecules of PrPSc (\( 2.5 \times 10^{-6} \) mg of scrapie brain tissue) seem to constitute a risk of infection.

We have found that the more frequent the injections, the higher the scrapie incidence. This suggests that after intraperitoneal inoculation, active or passive degradation of prions in the peritoneal cavity might be saturated when the intervals between injections are shorter. There is in vivo and in vitro evidence that macrophages and dendritic cells are involved in active prion degradation. In vitro, CD11c\(^+\) myeloid dendritic cells rapidly processed and degraded PrPSc (18). Incubation of scrapie brain homogenate with peritoneal macrophages greatly decreased prion infectivity, suggesting that macrophages can inactivate the scrapie agent in vitro (6). In vivo, administration of dichloromethylene diphosphonate before scrapie infection leads to macrophage depletion and accelerated scrapie, suggesting that macrophages may eliminate a fraction of the prion inoculum (1). Thus, macrophages and dendritic cells are likely to be involved in prion clearance after peripheral inoculation.

The scrapie incidence could depend on both the probability of infection at each given injection and the cumulative prion effect. In the cumulative prion effect hypothesis, the risk of infection could be determined by the total dose, accumulating with each challenge. Our results suggest a cumulative effect of prions, as we found that the incidence of scrapie was significantly higher when the same total dose was delivered through several injections rather than all at once. Our findings differ from Diringer’s experiment, where a total fixed dose had a significantly reduced probability of causing oral infection if the material was presented as multiple challenges (10). Gravener et al. have established statistical models to quantify the magnitude of the effect of repeated doses of prions over prolonged periods (12). They showed, by analyzing Diringer’s data, that although the risk of oral infection increases with repeated doses, it does so to a lesser degree than would be expected if challenges combine independently or in a cumulative manner. A detailed statistical study of our results is in progress using similar statistical models.

In conclusion, our data highlight possible infection mechanisms leading to development of prion diseases in iatrogenic exposures to very low prion contaminations. A high incidence of scrapie cases was observed in mice receiving repeated doses at low infectivity, whereas there was no disease in mice that were injected once with the same doses. Our findings constitute the first evidence that repeated injections of low prion doses constitute a risk for development of a prion disease even if the same total dose inoculated in a single challenge does not induce the disease. Multiple injections of subinfectious prion doses may thus be a potential hazard in vaccinations and repeated treatments, as has been the case in the past with pituitary-derived hGH.

**ACKNOWLEDGMENTS**

We thank Monique Dubois-Dalcq and Michel Goldberg for expert advice and critical reading of the manuscript, Mireille Hontebeyrie for mouse injections and expert discussions throughout the study, Karim Sebastien for animal care and collection of tissues, and Catherine...
Rybner-Barnier and Jacques Christophe Cossec for the initial Western blot studies.
This work was supported by GIS “infections à prions” and the Pasteur Institute, Paris, France.

REFERENCES

Downloaded from http://jvi.asm.org on September 8, 2017 by guest